A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303

BACKGROUND AND AIMS: CALGB 80303 was a randomized, phase III study in advanced pancreatic cancer patients treated with gemcitabine plus either bevacizumab or placebo. We prospectively collected germline DNA and conducted a genome-wide association study (GWAS) using overall survival (OS) as the endpo...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Innocenti, Federico, Owzar, Kouros, Cox, Nancy L., Evans, Patrick, Kubo, Michiaki, Zembutsu, Hitoshi, Jiang, Chen, Hollis, Donna, Mushiroda, Taisei, Li, Liang, Friedman, Paula, Wang, Liewei, Glubb, Dylan, Hurwitz, Herbert, Giacomini, Kathleen M., McLeod, Howard L., Goldberg, Richard M., Schilsky, Richard L., Kindler, Hedy L., Nakamura, Yusuke, Ratain, Mark J.
Формат: Artigo
Язык:Inglês
Опубликовано: 2011
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3412624/
https://ncbi.nlm.nih.gov/pubmed/22142827
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-11-1387
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы